Autolus Therapeutics (AUTL) FCF Margin (2017 - 2025)
Autolus Therapeutics' (AUTL) quarterly FCF Margin came in at 273.53% in Q4 2025, up 16885061.0% YoY from N/an in Q4 2024, and up 19.82% on a QoQ basis from 341.17% in Q3 2025.
Powered by 
Analysis
Autolus Therapeutics (AUTL) FCF Margin (2017 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has 9 years of FCF Margin data on file, last reported at 273.53% in Q4 2025.
- Quarterly FCF Margin rose 16885061.0% year-over-year to 273.53% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 401.4% (up 185297.0% YoY) and the FY2025 annual result came in at 401.4%, up 185498.0% from the prior year.
- FCF Margin advanced to 273.53% in Q4 2025, from 341.17% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 273.53% in Q4 2025 to a low of 169124.14% in Q4 2024.
- A 5-year average of 17309.17% and a median of 2049.91% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin slumped 869733 bps — and 2025, when it soared 16885061 bps.
- Tracing AUTL's FCF Margin over 5 years: stood at 16360.17% in 2021, then surged by 97 bps to 415.39% in 2022, then sank by 2372 bps to 10267.49% in 2023, then tumbled by 1547 bps to 169124.14% in 2024, then surged by 100 bps to 273.53% in 2025.
- The last three FCF Margin figures came in at 273.53% (Q4 2025), 341.17% (Q3 2025), and 382.63% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Autolus Therapeutics | 594.86 Mn | 393.23 Mn | 25.22 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -273.53% |
| Sep 30, 2025 | -341.17% |
| Jun 30, 2025 | -382.63% |
| Mar 31, 2025 | -933.07% |
| Dec 31, 2024 | -169,124.14% |
| Mar 31, 2024 | -406.99% |
| Sep 30, 2023 | -10,267.49% |
| Mar 31, 2023 | -3,568.96% |
| Dec 31, 2022 | -415.39% |
| Sep 30, 2022 | -1,570.16% |
| Mar 31, 2022 | -21,566.87% |
| Sep 30, 2021 | -16,360.17% |
| Jun 30, 2021 | -2,529.66% |
| Mar 31, 2021 | -14,588.48% |
| Dec 31, 2020 | -8,218.32% |
| Sep 30, 2020 | -9,842.69% |
| Jun 30, 2020 | -9,375.09% |
| Mar 31, 2020 | -8,478.40% |
| Jun 30, 2019 | -2,463.21% |
| Mar 31, 2019 | -1,723.37% |